Investment Holding Companies

MOOLEC SCIENCE SA C/WTS 30/01/2028(TO PUR COM)

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

FTAG

SBIO

LABU

MLECW

MLEC

Moolec Science shares fell 10.01% to $9.80 despite a breakthrough in producing bovine myoglobin in pea seeds. The company's innovation, achieved through a 28-month research project, enhances its position in the alternative protein sector. However, weak long-term trends and a significant 12-month decline of 89.07% overshadowed this progress. The stock is trading 28.1% above its 20-day SMA but 49.7% below its 200-day SMA, indicating mixed signals. Moolec is set to report earnings on April 20, 2026, with revised EPS and revenue estimates.

benzinga_article

iShares Biotechnology ETF

SPDR S&P Biotech

Invesco DB Agriculture FD ETF

First Trust Indxx Global Agri

VanEck Agribusiness ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Moolec Science SA

What's Going On With Moolec Stock Today?

VEGI

Agriculture Investment Group Corp. has acquired a controlling 65.1% stake in Moolec Science SA, effective April 1, 2026, by converting $9 million of preference shares into ordinary shares. This acquisition grants AIGC majority voting power and signifies a significant change in Moolec's shareholder structure. AIGC, based in the British Virgin Islands, focuses on agricultural investments and may review its position and purpose over time. The details were filed with the SEC on April 7, 2026.

TradingView

iShares MSCI Agriculture Producers ETF

Agriculture Investment Group Corp. Takes Control at Moolec Science SA with 65.1% Stake

Moolec Science Gains New Controlling Shareholder as AIGC Takes 65% Stake

Tip Ranks

Moolec Science Gains New Controlling Shareholder as AIGC Takes 65% Stake

FTXG

Moolec Science has restructured its board, appointing Daniel Core as a new director focused on quality and operations, while directors Aimar Dimo and Gloria Montaron Estrada resigned. This change aims to enhance governance and operational risk management as the company pursues its technology-driven strategy in the food industry. The latest analyst rating for Moolec Science (MLEC) stock is a Hold with a price target of $17.50, though financial fundamentals remain weak, impacting its overall rating.

First Trust NASDAQ Food & Beverage

Invesco Food & Beverage ETF

Moolec Science Overhauls Board With New Quality-Focused Director

Moolec Science SA's short interest has decreased by 36.93%, with 23,000 shares sold short, representing 4.15% of available trading shares. It would take an average of 1.0 days for traders to cover their short positions. Short interest is a key indicator of market sentiment, with a decrease suggesting a more bullish outlook. Compared to its peers, Moolec has a higher short interest percentage of 4.15%, while the peer average is 1.47%.

Looking Into Moolec Science SA's Recent Short Interest

ELAB

In Friday's pre-market session, Mangoceuticals (MGRX) saw a significant gain of 35.4%, reaching $0.48, while Moolec Science (MLEC) rose by 10.52% to $18.9. Other gainers included Healthy Choice Wellness (HCWC) up 10.29%, Celsius Holdings (CELH) up 5.5%, and Once Upon a Farm (OFRM) up 3.35%. Conversely, Davis Commodities (DTCK) fell 8.2% to $0.12, PMGC Holdings (ELAB) decreased by 6.9%, and Webuy Global (WBUY) declined by 5.56%.

PMGC

SPDR S&P Retail ETF

Celsius

Tradr 2X Long CELH Daily ETF

VanEck Retail ETF

SPDR FD Consumer Staples

Mangoceuticals

VG Consumer Stap

12 Consumer Staples Stocks Moving In Friday's Pre-Market Session

Advance Auto Parts (NYSE:AAP) reported Q4 earnings on February 13, 2026, beating estimates with an EPS of $0.86 compared to the expected $0.42, a 104.76% increase. However, revenue decreased by $23 million year-over-year. In the previous quarter, the company also exceeded EPS estimates, but shares dropped 7.04% the following day. Historical performance shows fluctuations in EPS and revenue across recent quarters. For more details, visit their earnings calendar.

Advance Auto Parts

Advance Auto Parts Earnings Review: Q4 Summary

Moolec Science Inc shares surged 90% after the company reported commercial-scale data from its U.S. GLASO safflower platform. The program produced oil with about 45% gamma-linolenic acid, among the highest levels at commercial scale. Moolec cultivated 1,100 acres of engineered safflower, achieving a 57% year-over-year yield increase. The stock traded around $11.12, up 118% on the day, as investors reacted positively to the update. The company aims to scale proven platforms and target recurring revenue in the nutrition market.

fidelity

Teucrium Wheat

Teucrium Corn Fd

Teucrium Soybean

Moolec Science (MLEC) Stock Explodes 90% After GLA Update

Moolec Science shares are trading higher after the company announced results from the crushing process of its U.S. GLASO1 safflower platform.

In Singapore on February 4, 2026, NeuroAiD™II received acknowledgment due to its strong clinical evidence and distinctive formulation. The recognition also emphasized the rigor of manufacturing, reproducibility, and quality control of NeuroAiD™II, underscoring its reliability and value in aiding support.

Unusual Whales

Moleac's NeuroAiD™II awarded Gold accreditation for clinical evidence and formulation uniqueness in Singapore.

MOOLEC SCIENCE SA C/WTS 30/01/2028(TO PUR COM)(MLECW.US)

What's Going On With Moolec Stock Today?

Agriculture Investment Group Corp. Takes Control at Moolec Science SA with 65.1% Stake

Moolec Science Gains New Controlling Shareholder as AIGC Takes 65% Stake

Moolec Science Overhauls Board With New Quality-Focused Director

Looking Into Moolec Science SA's Recent Short Interest

12 Consumer Staples Stocks Moving In Friday's Pre-Market Session

Advance Auto Parts Earnings Review: Q4 Summary

Moolec Science (MLEC) Stock Explodes 90% After GLA Update

Moolec Science shares are trading higher after the company announced results from the crushing process of its U.S. GLASO1 safflower platform.

Moleac's NeuroAiD™II awarded Gold accreditation for clinical evidence and formulation uniqueness in Singapore.